Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Viking Therapeutics, Inc. (VKTX) had Normalized Income after Taxes of $-359.69M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-359.64M |
|
-- |
|
-- |
|
$393.34M |
|
$-393.34M |
|
$33.70M |
|
$-359.64M |
|
$-359.69M |
|
$-359.64M |
|
$-359.64M |
|
$-359.64M |
|
|
Normalized Income after Taxes |
$-359.69M |
$-393.34M |
|
$-402.14M |
|
112.67M |
|
112.67M |
|
$-3.19 |
|
$-3.19 |
|
| Balance Sheet Financials | |
$715.60M |
|
-- |
|
$0.13M |
|
$715.73M |
|
$76.67M |
|
-- |
|
-- |
|
$76.67M |
|
$639.06M |
|
$639.06M |
|
$639.06M |
|
114.79M |
|
| Cash Flow Statement Financials | |
$-278.69M |
|
$341.39M |
|
$76.44M |
|
$26.68M |
|
$165.81M |
|
$139.13M |
|
$40.82M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.33 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-278.69M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-56.28% |
|
-56.28% |
|
-50.25% |
|
-56.28% |
|
$5.57 |
|
$-2.47 |
|
$-2.47 |
|